Mucoepidermoid carcinoma (MEC) and adenosquamous carcinoma (ASC), the same or different entities?
Mucoepidermoid carcinoma (MEC) and adenosquamous carcinoma (ASC), the same or different entities?
复制标题
DOI：
10.1038/s41379-022-01100-z
复制
发表时间：
2022-10
期刊：
影响因子：
7.5
通讯作者：
Indave, Blanca Iciar
中科院分区：
文献类型：
--
作者：
White, Valerie A.;Hyrcza, Martin D.;Lennerz, Jochen K.;Thierauf, Julia;Lokuhetty, Dilani;Cree, Ian A.;Indave, Blanca Iciar
粘液表皮样癌（MEC）和腺鳞癌（ASC）具有重叠的组织病理学表现和发生部位，这可能导致诊断困难，影响后续治疗。我们对科学文献进行了系统回顾，以确定MEC和ASC的分子改变是否有足够的差异，以帮助对这两种实体进行分类。我们在Medline、Embase和Web of Science中检索了报告ASC和/或MEC分子测定的研究，并筛选了检索到的合格记录。两名独立研究人员审查了纳入研究，评估了方法学质量并提取了数据。在8623条识别的记录中，128篇文章被纳入分析：5篇使用相同方法比较了同一研究中的两种肿瘤，123篇分别检查了肿瘤。除一篇文章外，所有文章均为方法学质量中等至较差的病例系列。检查两种肿瘤的5篇出版物显示，52/88（59%）MEC和0%的110 ASC具有通过FISH和/或RT-PCR检测到的MAML 2基因重排，但未研究其他基因。在整个系列中，MEC在1337/2009（66.6%）所研究的肿瘤中具有MAML 2基因重排。分别检查肿瘤的文章发现，MEC有EGFR（11/329例，3.3%）、KRAS（11/266，4.1%）和ERBB 2（9/126，7.1%）突变，而ASC有EGFR（660/1705，38.7%）、KRAS（143/625，22.9%）和ERBB 2（6/196，3.1%）突变。胰腺ASC中复发突变水平最高，其中（108/126，85.7%）报告了KRAS突变。ASC中EGFR突变的数量和类型与肺腺癌相似。根据系统评价方法的标准，尽管检索到大量的研究，我们没有找到足够的证据来证明MEC或ASC的独特分子特征可以明确地帮助其分类，特别是在MAML 2重排阴性的组织学困难病例中。本综述中包含的病例系列表明MAML 2重排与MEC诊断的相关性，这些发现应通过具有适当研究设计的额外研究予以证实。
Mucoepidermoid carcinoma (MEC) and adenosquamous carcinoma (ASC) have overlapping histopathological appearances and sites of occurrence, which may cause diagnostic difficulty impacting subsequent treatment. We conducted a systematic review of the scientific literature to determine whether molecular alterations were sufficiently different in MEC and ASC to aid in classifying the two entities. We searched Medline, Embase and Web of Science for studies reporting molecular determinations of ASC and/or MEC and screened retrieved records for eligibility. Two independent researchers reviewed included studies, assessed methodological quality and extracted data. Of 8623 identified records, 128 articles were included for analysis: 5 which compared the two tumors in the same investigation using the same methods and 123 which examined the tumors separately. All articles, except one were case series of moderate to poor methodological quality. The 5 publications examining both tumors showed that 52/88 (59%) MEC and 0% of 110 ASC had rearrangement of the MAML2 gene as detected by FISH and/or RT-PCR, but did not investigate other genes. In the entire series MEC had MAML2 gene rearrangement in 1337/2009 (66.6%) of tumors studied. The articles examining tumors separately found that MEC had mutations in EGFR (11/329 cases, 3.3%), KRAS (11/266, 4.1%) and ERBB2 (9/126, 7.1%) compared with ASC that had mutations in EGFR (660/1705, 38.7%), KRAS (143/625, 22.9%) and ERBB2 (6/196, 3.1%). The highest level of recurrent mutations was in pancreatic ASC where (108/126, 85.7%) reported mutations in KRAS. The EGFR mutations in ASC were similar in number and kind to those in lung adenocarcinoma. By standards of systematic review methodology and despite the large number of retrieved studies, we did not find adequate evidence for a distinctive molecular profile of either MEC or ASC that could definitively aid in its classification, especially in histologically difficult cases that are negative for MAML2 rearrangement. The case series included in this review indicate the relevance of MAML2 rearrangement to support the diagnosis of MEC, findings that should be confirmed by additional research with adequate study design.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
7.5
作者：
Kardon, DE;Thompson, LDR;Heffess, CS
通讯作者：
Heffess, CS
DOI：
10.1158/1078-0432.ccr-16-0720
发表时间：
2017-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Kang H;Tan M;Bishop JA;Jones S;Sausen M;Ha PK;Agrawal N
通讯作者：
Agrawal N
影响因子：
3.5
作者：
Chenevert, Jacinthe;Barnes, Leon E.;Chiosea, Simion I.
通讯作者：
Chiosea, Simion I.
影响因子：
2.5
作者：
Keelawat, S;Liu, CZ;Barnes, L
通讯作者：
Barnes, L